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Abstract
Background: A novel alkylating agent, temozolomide, has proven efficacious in the treatment of
malignant gliomas. However, expression of O6-methylguanine-DNA methyltransferase (MGMT)
renders glioma cells resistant to the treatment, indicating that identification of mechanisms
underlying the gene regulation of MGMT is highly required. Although glioma-derived cell lines have
been widely employed to understand such mechanisms, those models harbor numerous
unidentified genetic lesions specific for individual cell lines, which complicates the study of specific
molecules and pathways.
Results:  We established glioma models by transforming normal human astrocyte cells via
retroviral-mediated gene transfer of defined genetic elements and found that MGMT was
downregulated in the transformed cells. Interestingly, inhibitors of DNA methylation and histone
deacetylation failed to increase MGMT protein levels in the transformed astrocyte cells as well as
cultured glioblastoma cell lines, whereas the treatment partially restored mRNA levels. These
observations suggest that downregulation of MGMT may depend largely on cellular factors other
than promoter-hypermethylation of MGMT genes, which is being used in the clinic to nominate
patients for temozolomide treatment. Furthermore, we discovered that Valproic acid, one of
histone deacetylase inhibitors, suppressed growth of the transformed astrocyte cells without
increasing MGMT protein, suggesting that such epigenetic compounds may be used to some types
of gliomas in combination with alkylating agents.
Conclusion: Normal human astrocyte cells allow us to generate experimental models of human
gliomas by direct manipulation with defined genetic elements, in contrast to tumor-derived cell
lines which harbor numerous unknown genetic abnormalities. Thus, we propose that the study
using the transformed astrocyte cells would be useful for identifying the mechanisms underlying
MGMT regulation in tumor and for the development of rational drug combination in glioma
therapies.
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Background
Gliomas, accounting for 30% of adult primary brain
tumors, are the most common primary tumors of the cen-
tral nervous system and are classified into four clinical
grades, with the most aggressive and lethal tumors being
grade IV glioblastoma multiforme (GBM) [1,2]. The
median survival of GBM patients is less than one year
from initial diagnosis, and many of the commonly used
chemotherapeutic agents have limited effects on these
malignant tumors [3]. Recently, there has been increasing
hope that temozolomide, a novel alkylating agent, will
prove efficacious in the treatment of human glioma [4,5].
However, a number of studies have suggested that, in
tumors,  O6-methylguanine-DNA methyltransferase
(MGMT) provides resistance to treatment with temozolo-
mide, unless expression is lost by promoter methylation
or there is direct inhibition of MGMT activity [6]. Consid-
ering the attractive efficacy of temozolomide, one of the
greatest challenges facing the field may be to identify ther-
apeutic agents that suppress MGMT expression, as such
drugs may sensitize resistant glioma cells to temozolo-
mide. Thus, establishment of more sophisticated systems
to understand the functions and regulation of MGMT are
highly desired.
Normal human cells, genetically modified by retroviral-
mediated gene transfer, have proven important, because
such systems are useful for identifying factors directly con-
tributing to tumorigenesis, in contrast to tumor-derived
cell lines which harbor numerous unknown genetic
abnormalities [7,8]. GBMs are believed to arise from
astrocyte cells by means of stepwise accumulation of
genetic abnormalities [4,9], and immortalized normal
human astrocyte (NHA) cells had been established by
introducing the telomerase catalytic subunit (hTERT) in
combination with human papillomavirus E6/E7 to inacti-
vate both p53 and pRb pathways [10]. It had been system-
atically demonstrated that the immortalized NHA cells,
expressing activated Ras (H-RasV12) or expressing both
H-RasV12 and an active form of Akt (myrAKT), formed
tumors consistent with human anaplastic astrocytoma or
GBM in intracranial- and flank-xenografts models
[10,11]. These studies indicate that such systems are use-
ful for glioma research to understand direct functions and
regulation of genetic elements during transformation and
gliomagenesis.
Here we created similar experimental models using NHA
cells by introducing the simian virus 40 early region
(SV40ER) instead of human papillomavirus E6/E7. The
SV40ER  encodes both small-t antigen, a suppressor of
protein phosphatase 2A (which is downregulated in half
of human glioma) [12] and large-T antigen, which directly
binds to and inactivates p53, as well as pRB and the
closely related proteins p107 and p130 [13]. Using such
genetically modified NHA cells, we demonstrate that
MGMT is downregulated during oncogene-mediated
transformation of astrocyte cells. Since our results indicate
that downregulation of MGMT expression was not prima-
rily dependent upon promoter hypermethylation, inhibi-
tors of DNA methylation or histone deacetylases
(HDACs) may be used in combination with alkylating
agents for improved treatment of some GBM cases. We
propose that the NHA cell systems are useful for investi-
gating the mechanisms underlying MGMT expression and
for improving glioma therapies.
Results
To create an experimental model of human gliomas, NHA
cells were introduced with genes for hTERT (T), SV40ER
(S), H-RasV12 (R), and myrAKT (A) (Figure 1A; NHA/TS,
NHA/TSR, NHA/TSRA cells). The NHA/TS cells grew
much faster than parental NHA cells, exhibiting continu-
ous growth beyond population-doubling 50 (data not
shown). However, the NHA/TS cells did not form colo-
nies in soft agar or tumors in xenografts into recipient
nude mice (Figure 1B; Table 1), indicating that the NHA/
TS cells were immortalized but not transformed. In con-
trast, the NHA/TSR and NHA/TSRA cells formed a consid-
erable number of colonies in soft-agar, as well as tumors
in flank-xenografts into nude mice (Table 1). NHA/TSRA
cells displayed much more refractile morphology and
loose attachment to the culture dish relative to NHA/TSR
cells (Figure 1B). Although the difference in the anchor-
age-independent growth property was quite subtle
between NHA/TSR and NHA/TSRA cells (Table 1), the his-
topathological features of two types of flank xenografts
were clearly different. In tumor tissues formed by NHA/
Table 1: Summary of soft agar colony formation assay and 
xenograft propagation experiment: NHA and NIH3T3 cells 
infected with retroviral vectors expressing hTERT (T), SV40ER 
(S), H-RasV12 (R), myrAKT (A), and/or MGMT as well as 
parental NHA cells were subjected to the soft-agar colony 
formation and xenograft propagation assays.
Cell types Colony numbers a % Tumor incidence (n) b
NHA (parental) 0 ND
NHA/TS 0 0 (3)
NHA/TSR 664 ± 19 100 (3)
NHA/TSRA 736 ± 51 100 (3)
NHA/TSR + MGMT 649 ± 34 ND
NIH3T3/R 1440 ± 56 ND
NIH3T3/R + MGMT 1344 ± 88 ND
aNHA (2 × 104) and NIH3T3 cells (1 × 104) were plated in soft-agar 
(0.36% top agar containing 5% fetal calf serum in 60-mm dishes) and 
incubated for 21 days and 14 days, respectively. Colonies were stained 
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
and the numbers of stained colonies were counted. Results represent 
mean ± SD from two independent triplicate experiments.
b3 × 106 cells were injected s.c. into nude mice. n, number of animals 
treated. ND, not done.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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TSR cell injection, atypical astrocytic cells with higher cel-
lularity exhibits histopathological features of Grade III gli-
oma as anaplastic astrocytoma of WHO classification. On
the other hand, the TSRA-xenografts composed of similar
atypical astrocytes displayed numerous areas of necrosis
with nuclear pseudo-palisading pattern. Consistent with
the histological feature as GBM, the immunohistochemi-
cal index of Ki-67 positivity is higher in NHA/TSRA
tumors than those of NHA/TSR derived tumors (Figure 2).
Using the NHA cell system described above, we found that
the mRNA level of MGMT was decreased in immortalized
(NHA/TS) and transformed (NHA/TSR and NHA/TSRA)
cells and that MGMT expression was also downregulated
in the flank xenografts derived from NHA/TSR and NHA/
TSRA cells (Figure 3A). Immunoblot analyses also dem-
onstrated that introduction of SV40ER decreased MGMT
level in NHA cells and that the levels were further
decreased in transformed NHA cells (Figure 3B). Con-
versely, in human lung fibroblasts TIG3/T cells (TIG3 cells
expressing hTERT) [14], neither SV40ER nor H-RasV12
suppressed MGMT expression (Figure 3B), suggesting the
astrocyte-specific mechanisms of MGMT regulation. This
is an interesting observation as TIG3/TS cells are refractory
to Ras-induced genetic alteration [15,16], morphological
changes [17] and thereby cellular transformation [14].
Although such observation prompted us to further test the
tumor suppressive functions of MGMT, the additional
expression of MGMT in NHA/TSR and NIH3T3/R cells
(NIH3T3 cells transformed by H-RasV12) failed to sup-
press anchorage-independent growth (Table 1), suggest-
ing that MGMT may be unable to restore transformed
phenotypes. In fact, tumors have long been noted to be
heterogeneous in MGMT expression [5,6], and approxi-
mately half of malignant gliomas expressed MGMT [18].
However, it is possible that the mechanisms underlying
resistance to downregulation of MGMT may render TIG3
fibroblasts refractory with respect to oncogene-mediated
transformation, because MGMT functions to protect nor-
mal cells from exogenous carcinogens [6]. In support of
this idea is the observation that MGMT mRNA was down-
regulated in v-fos-transformed [19,20] and Ras-trans-
formed (TA unpublished data) rodent fibroblasts,
showing highly malignant phenotypes.
To understand the mechanism underlying the downregu-
lation of MGMT in transformed NHA cells, we first ana-
Histological features of s.c. xenografts derived from the  transformed NHA cells Figure 2
Histological features of s.c. xenografts derived from 
the transformed NHA cells. Formalin-fixed paraffin-
embedded tissue sections (5-µm-thick) of xenografts derived 
from NHA/TSR (left) and NHA/TSRA (right) cells were sub-
jected to histological analyses. Low- (top) and high- (middle) 
magnification images (H&E staining; scale bar, 200 µm) and 
immunohistochemistry using an anti-Ki-67 antibody (bottom) 
are shown.
Establishment of immortalized and transformed NHA cells Figure 1
Establishment of immortalized and transformed 
NHA cells. (A) Protein extracts (10 µg) from NHA cells 
infected with retroviral vectors expressing indicated genes 
(T, hTERT: S, SV40ER: R, H-RasV12; A; myrAKT) were ana-
lyzed by immunoblotting. Asterisk, active form of AKT 
(myrAKT) was distinguishable from wild-type form. (B) The 
morphologies (top panels) and anchorage-independent 
growth properties (bottom panels) of NHA/TS, NHA/TSR, 
and NHA/TSRA cells are shown.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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lyzed the MGMT expression following treatment with 5-
aza-2'-deoxycytosine (5-aza-dC) and/or Valproic acid
(VPA), because it has been widely acknowledged that
aberrant methylation of MGMT-promoter contributes to
the gene expression changes [6]. Inhibitors of HDACs,
such as VPA and trichostatin A, act synergistically with 5-
aza-dC (a DNA methyltransferase inhibitor and demeth-
ylating agent in dividing cells) to further increase the
expression of genes silenced in association with promoter
hypermethylation [21]. Reverse transcriptase (RT)-PCR
analysis revealed that treatments with 5-aza-dC alone or
combined treatment with 5-aza-dC/VPA slightly increased
MGMT mRNA levels, when the PCR was performed in a
condition where the positive control reaction (mRNA
from the NHA/TS cells) was saturated (data not shown),
suggesting that the downregulation may have been par-
tially mediated by promoter hypermethylation. However,
combined treatment with 5-aza-dC/VPA was insufficient
to restore MGMT protein levels in NHA/TSR and NHA/
TSRA cells whereas the treatment clearly induced acetylta-
tion and demethylation of histone H3 (Figure 4A), sug-
gesting that additional factors, which are expressed in the
parental NHA cells but inactivated in the transformed
NHA cells, may be required to increase MGMT protein lev-
els.
In an attempt to identify such missing factors contributing
to gene regulation of MGMT, we tested if the expression of
wild type p53 restores MGMT levels, as MGMT was
slightly decreased in the NHA/TS cells where p53 is inac-
tivated by large T antigen (Figure 3). Although several gli-
oma studies have demonstrated correlations between
inactivation of the p53 pathway and lower levels and/or
activity of MGMT [22-24], the introduction of wild type
p53 failed to restore MGMT protein levels in transformed
NHA cells (Figure 4B). We also confirmed previous
reports that both U87MG (harboring wild type p53) and
U251MG (harboring p53  mutations) glioma cells
expressed low or no levels of MGMT [25-27]. We further
found that treatment with 5-aza-dC/VPA failed to induce
MGMT protein expression in both cell lines (Figure 4C),
whereas the treatment slightly increased the mRNA levels
(by RT-PCR; data not shown). Since gliomas harboring
p53 mutations and immuno-positive for p53 (G2, G7,
and G8) as well as gliomas harboring wild type p53 and
immuno-negative for p53 (G4 and G10) expressed
MGMT mRNA (Figure 5, Table 2), MGMT might be regu-
lated primarily by the factors other than p53 in gliomas.
Conversely, MGMT is clearly downregulated in normal
astrocyte cultures from p53 deficient mice [28], suggesting
the differences in the regulation of MGMT between nor-
mal and transformed cells.
Since MGMT seems to be regulated in several ways, it is
possible that inhibitors of HDACs may be used for thera-
MGMT is downregulated in immortalized and transformed  NHA cells Figure 3
MGMT is downregulated in immortalized and trans-
formed NHA cells. (A) The expression of MGMT mRNA 
in NHA (parental; lane 1), NHA/T (lane 2), NHA/TS (lane 3), 
NHA/TSR (lane 4), and NHA/TSRA cells (lane 5) were ana-
lyzed by semi-quantitative RT-PCR. The levels in flank 
xenografts derived from the NHA/TSR and NHA/TSRA cells 
were also tested (lanes 6 and 7). (B) Protein extracts (10 µg) 
from NHA (lanes 1–4) and TIG3 cells (lanes 5–7) infected 
with retroviral vectors expressing indicated genes (T, 
hTERT: S, SV40ER: R, H-RasV12; A; myrAKT) were analyzed 
by immunoblotting.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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pies for some glioma patients in combination with
alkylating agents, such as temozolomide. Since VPA,
which inhibits both class I and class II HDACs [29], has
displayed potent in vitro and in vivo antitumor activities
against brain tumor cells [30], it is one attractive candi-
date agent. The treatment with VPA appreciably inhibited
growth of the NHA/TSRA cells in a dose dependent man-
ner (Figure 6A) and two-week-treatment with 0.5 mM
VPA (within the range of serum levels achieved in pediat-
ric high-grade glioma patients) [31] suppressed anchor-
age-independent growth (Figure 6B). Although
hyperacetylation of histone H3 was noted in the NHA/
TSRA cells treated with VPA for two weeks, the treatment
failed to restore protein (Figure 6C) and mRNA levels of
MGMT (data not shown). Since protein levels of p21WAF1
and p27KIP1 were elevated in VPA-treated NHA/TSRA cells
(Figure 6C), the antiproliferative effect might be medi-
ated, at least in part, by cell cycle arrest, as widely acknowl-
edged. These findings suggest that HDAC inhibitors,
which suppress tumor cell growth without affecting
MGMT expression, may be used in combination with
alkylating agents to some glioma patients.
Discussion
Much of our understanding of the molecular basis of gli-
omagenesis derives from the study of established cell lines
that are explanted from human tumors. Such cell lines are
often assumed to be representative of the original dis-
eases, and they have been extensively employed for the
identification and preclinical testing of potential thera-
peutic compounds. However, they harbor an unknown
number of genetic lesions, which complicates the study of
specific molecules and pathways. Indeed, with respect to
p53-mediated MGMT regulation, there have been contra-
dictory observations, where transient knockdown of p53
caused MGMT downregulation in SF767 glioma cells
without affecting promoter methylation [28] but
increased MGMT expression in T98 cells [27]. Since such
discrepancy may depend on unidentified mutations spe-
cific for individual cell lines, it is difficult to provide con-
stant conclusions using tumor-derived cell lines alone.
Therefore, normal human cells as well as genetically engi-
neered mouse models will prove very useful, which allow
us to generate experimental models of human cancers by
direct manipulation with defined genetic elements [7,8].
Here we established glioma models from NHA cells and
demonstrated that MGMT is downregulated in the trans-
formed astrocyte cells. Although numerous studies have
proposed the strong linkage between MGMT expression
and promoter hypermethylation of the gene, treatment
with epigenetic compounds (5-aza-dC/VPA) was unable
to increase MGMT protein levels in the transformed NHA
cells or in cultured tumor cells. Some previous reports
demonstrated the epigenetic regulation of MGMT expres-
Neither treatment with 5-aza-dC/VPA nor p53 expression  restores MGMT protein levels in transformed NHA cells Figure 4
Neither treatment with 5-aza-dC/VPA nor p53 
expression restores MGMT protein levels in trans-
formed NHA cells. (A) Protein extracts (10 µg) from the 
transformed NHA cells treated (+) and untreated (-) with 5-
aza-dC/VPA were analyzed by immunoblotting. (B) Protein 
extracts (10 µg) from the transformed NHA cells infected 
with wild type p53 (+) and control virus (-) were analyzed by 
immunoblotting. (C) Protein extracts (10 µg) from glioma 
cell lines treated (+) and untreated (-) with 5-aza-dC/VPA 
were analyzed by immunoblotting.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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sion by treating tumor cell lines with 5-aza-dC and testing
the MGMT levels by RT-PCR [32,33]. However, based on
the data presented here, such limited evaluation might
not be sufficient, as RT-PCR assay overestimates the
MGMT restoration. Since inappropriate evaluation would
mislead the development of advanced therapies, protein
levels or enzyme activity of MGMT in the cells treated with
such compounds should be examined and compared with
those in normal cells. In fact, the use of alkylating agents
in combination with HDAC inhibitors has been ham-
pered, probably because it has been suspected that such
agents would increase MGMT expression. However, we
showed that two-week-treatment with VPA inhibited
tumor cell growth without increasing MGMT expression,
suggesting potential clinical use although further preclin-
ical studies are required.
As the treatment with 5-aza-dC/VPA slightly increased
mRNA levels of MGMT in cultured glioma cells (including
U87MG, U251MG and transformed NHA cells), methyla-
tion status might be involved in MGMT regulation to
some extent. However, such treatment was insufficient to
restore protein expression of MGMT, suggesting that the
regulation mechanisms may largely depend on other cel-
lular factors. Although p53 does not seem to contribute
directly to MGMT expression, it is possible that other tran-
scription factors, whose expressions have been downregu-
lated or silenced during transformation and
gliomagenesis, may collaborate with HDAC inhibitors to
increase MGMT protein. Interestingly, the sonic hedgehog
pathway has been shown to regulate the self-renewal of
CD133-positive glioblastoma cells, which were resistant
to temozolomide treatment [34]. Furthermore, some of
CD133-positive glioma cultures highly expressed MGMT
as well as target genes of the sonic hedgehog pathway
[35]. Thus, it is possible that the regulation of MGMT
expression may be partially mediated by the sonic hedge-
hog pathway in some cases.
Conclusion
As discussed above, MGMT seems to be regulated by a
number of ways in gliomas. The detailed mechanisms
should be further analyzed as MGMT level is a critical
determinant for efficacy of therapies with alkylating
agents. Thus, identification of molecules and compounds
that increase MGMT expression by screening NHA/TSR or
NHA/TSRA cells with cDNA- and chemical-libraries
would be very useful for the development of rational drug
combination. We propose that the NHA cell system cre-
ates refined human glioma models for the systematic dis-
section of genetic alterations and elucidation of the
complexities of the signaling pathways important for gli-
omagenesis. These systems also provide powerful means
to find and authenticate molecules of particular promise
for therapeutic targeting, and the present study provides
an important proof-of-principle test for such systems.
Methods
Clinical samples
Brain tumor specimens were obtained, after informed
consent, from patients undergoing tumor resection at the
Kashiwaba Neurosurgical Hospital.
Cell culture
NHA cells (Cambrex Bio Science, Walkersville, MD, USA)
were cultured in the astrocyte growth medium (AGM;
Cambrex Bio Science). All other cells including immortal-
ized NHA cells were maintained in Dulbecco's modified
eagle medium (Seikagaku Co., Tokyo, Japan), supple-
mented with 10% fetal calf serum, 1 mM Glutamine, 50
Table 2: Diagnosis and p53 status of human gliomas: The index of Ki-67 staining and p53 status (mutation and immunopositivity) are 
listed with patient ID, age at surgery, gender (F, female; M, male), and clinical diagnosis (GBM, glioblastoma, WHO grade IV; AA, 
anaplastic astrocytoma, WHO grade III, AE anaplastic ependymoma, WHO grade III). Images of H&E staining and 
immunohistochemistry are shown [see additional file 1].
ID Age Gender Diagnosis Ki-67 (%) a p53 mutations b p53 staining c
G1 73 F GBM 4.0 N +
G2 58 M GBM 44.3 R156P, H214R ++
G3 36 M GBM 24.8 N -
G4 77 F GBM 92.5 N -
G5 53 M GBM 12.6 N ++
G6 61 M GBM 43.6 N +
G7 83 M GBM 53.1 H193P ++
G8 28 M GBM 29.0 H214R +++
G9 55 F AA 3.3 N +++
G10 42 F AE 42.6 N -
aMIB-1 labeling index (by anti-Ki-67 antibody) was analyzed using the MetaMorphV7.0 software (Molecular Cevices, Downingtown, PA, USA), by 
counting 500–2,000 nuclei per case.
bp53 cDNA was amplified by RT-PCR and the products were directly sequenced. N, no mutation was detected.
cStaining intensity was classified into four categories: +++, strong; ++, moderate; +, weak; -, negative.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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units/ml penicillin G and 50 µg/ml streptomycin. All cul-
tures were incubated at 37°C under a humidified atmos-
phere of 95% air and 5% CO2. For the combination
treatment (5-aza-dC/VPA), 5-aza-dC (1 µM; Sigma, St.
Louis, MO, USA) was added for an initial incubation of 48
h, after which VPA (1 mM; Sigma) was added for an addi-
tional 24 h.
Retroviral vectors and retroviral-mediated gene transfer
A cDNA fragment encoding murine ecotropic retrovirus
receptor (EcoVR) was obtained from the retroviral plas-
mid pCX4hyg-EcoVR [14], and then subcloned into
pCX4redEx vector [GenBank: AB296084]. Myc-His-tagged
active form of mouse AKT1 cDNA, which has N-terminal
myristoylation, was isolated from the pUSEamp-myr-AKT
plasmid (Upstate, Charlottesville, VA, USA) and sub-
cloned into pCX4bleo retroviral vector [GenBank:
AB086388]. Full-length cDNAs for human MGMT  and
p53 were generated by PCR and subcloned into pCX4bleo
and pCX4gfp [GenBank: AB296083] retroviral vectors,
respectively. Primer sequences used in this experiment
included 5'-ATG GAC AAG GAT TGT GAA-3' and 5'-TCA
GTT TCG GCC AGC AGG-3' for human MGMT and 5'-
CTG AAT TCA TGG AGG AGC CGC AGT CAG-3' and 5'-
CCG AAT TCA GTC TGA GTC AGG CCC TTC-3' for human
p53. Other retroviral vectors and the procedure of retrovi-
ral-mediated gene transfer were described previously [14].
The murine EcoVR was first introduced into NHA cells by
using amphotropic virus, in order to make human cells
susceptible to the subsequent infection with ecotropic
viral vectors. Infected cell populations were selected in
blasticidin S (20 µg/ml), G418 (1000 µg/ml), puromycin
(500 ng/ml), or zeocine (500 µg/ml) for two weeks. In all
cases, cultures arose from polyclonal expansion of
infected cells.
VPA inhibits cell growth in transformed human astrocyte  cells Figure 6
VPA inhibits cell growth in transformed human 
astrocyte cells. (A) Dose-dependent anti-proliferative 
effects of VPA were shown. NHA/TSRA cells were treated 
with 0, 0.5 and 1.0 mM VPA for 14 days. Cell numbers were 
counted every other day and results were expressed in the 
mean of two independent experiments. (B) NHA/TSRA cells, 
treated (0.5 mM) and untreated (0 mM) with VPA for two 
weeks, were subjected to soft-agar colony formation assay. 2 
× 104 cells were plated, incubated at 37°C for 21 days and 
stained with 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetra-
zolium bromide. Note VPA was not included in the assay 
media. (C) Protein extracts (10 µg) from NHA/TSRA cells 
treated with VPA were analyzed by immunoblotting using 
indicated antibodies.
Expression of MGMT RNA in human glioma tissues Figure 5
Expression of MGMT RNA in human glioma tissues. 
The mRNA levels of MGMT expression in human glioma tis-
sues were analyzed by semi-quantitative RT-PCR.Molecular Cancer 2007, 6:36 http://www.molecular-cancer.com/content/6/1/36
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RT-PCR
Total RNA was isolated with the TRI Reagent (Sigma) and
reverse transcribed into cDNA using the oligo-dT primer
(Invitrogen, Carlsbad, CA, USA) and the Superscript II
(Invitrogen). The levels of MGMT were analyzed by PCR
with the KOD plus DNA polymerase (Toyobo, Tokyo,
Japan) using the primers described above. PCR primers
for  Glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
were described previously [15].
Soft-agar colony formation assay and xenograft 
propagation
Soft-agar colony formation assay [15] and xenograft prop-
agation [36] were carried out as described. Female ath-
ymic nude mice (BALB/cAJcl-nu/nu) were purchased from
Clea Japan (Tokyo, Japan) and all animal procedures were
carried out according to the protocol approved by the
institutional Animal Care and Use Committee at
Hokkaido University Graduate School of Medicine.
Histological analysis and immunohistochemistry
Formalin-fixed paraffin-embedded tissues were sectioned
and stained with haematoxylin and eosin (H&E) using
standard protocols. Immunohistochemistry was per-
formed using anti-Ki-67 (MIB-1; Dako, Glostrup, Den-
mark) and anti-p53 (DO-7; Dako) monoclonal
antibodies.
Immunoblotting
Protein determination, SDS-PAGE and immunoblotting
were carried out as described previously [37], and reactive
protein signals were visualized by chemiluminescence
using the ECL reagent (Amersham, Piscataway, NJ, USA)
or the SuperSignal West Femto reagent (Pierce, Rockford,
IL, USA). Antibodies were obtained from the following
sources: anti-SV40 large T antigen (Ab-1) and anti-SV 40
small t antigen (Ab-3) monoclonal antibodies (Oncogene
Research Product, San Diego, CA, USA); anti-p53 and
anti-AKT polyclonal antibodies (Cell Signaling Technol-
ogy, Beverly, MA, USA); anti-RAS and anti-p27KIP1 mono-
clonal antibodies (Transduction Laboratories, Lexington,
KY, USA); anti-dimethylated Histone-H3 (Me-H3) and
anti-acetylated Histone-H3 (Ac-H3) polyclonal antibod-
ies (Upstate); anti-MGMT (MT3.1) and anti-ACTIN mon-
oclonal antibodies (Chemicon International, Temecula,
CA, USA); an anti-p21WAF1 monoclonal antibody (Ab-1;
Calbiochem, San Diego, CA, USA); an anti-hTERT (L20)
polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
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